Современные подходы к специфической профилактике пневмококковой инфекции: кому, когда, что?


Цитировать

Полный текст

Открытый доступ Открытый доступ
Доступ закрыт Доступ предоставлен
Доступ закрыт Доступ платный или только для подписчиков

Аннотация

В обзоре дана характеристика современных пневмококковых полисахаридной и конъюгированных вакцин, обсуждены показания к их применению у разных категорий пациентов, представлены схемы иммунизации в разных клинических ситуациях.

Полный текст

Доступ закрыт

Об авторах

И. В Андреева

НИИ антимикробной химиотерапии Смоленского государственного медицинского университета Минздрава России

Email: Irina.Andreeva@antibiotic.ru
канд. мед. наук, ст. науч. сотр., доц. НИИ антимикробной химиотерапии 214019 Смоленск, ул. Крупская, д. 28, а/я 5

О. У Стецюк

НИИ антимикробной химиотерапии Смоленского государственного медицинского университета Минздрава России

Email: olga@antibioitc.ru
канд. мед. наук, ст. науч. сотр. НИИ антимикробной химиотерапии химиотерапии Смоленского государственного медицинского университета Минздрава России

Р. С Козлов

НИИ антимикробной химиотерапии Смоленского государственного медицинского университета Минздрава России

Email: roman@antibiotic.ru
д-р мед. наук, проф., дир. НИИ антимикробной химиотерапии Смоленского государственного медицинского университета Минздрава России; Главный внештатный специалист Минздрава России по клинической микробиологии и антимикробной резистентности; Президент Межрегиональной ассоциации по клинической микробиологии и антимикробной химиотерапии

Список литературы

  1. Feldman C., Anderson R. Recent advances in our understanding of Streptococcus pneumoniae infection. F1000Prime Rep. 2014; 6: 82.
  2. Said M.A., Johnson H.L., Nonyane B.A.S., Deloria-Knoll M., O,Brien K.L. AGEDD Adult Pneumococcal Burden Study Team. Estimating the burden of pneumococcal pneumonia among adults: a systematic review and meta-analysis of diagnostic techniques. PLoS One 2013; 8: e60273.
  3. Чучалин А.Г., Синопальников А.И., Козлов Р.С., Авдеев С.Н., Тюрин И.Е., Руднов В.А., Рачина С.А., Фесенко О.В. Клинические рекомендации по диагностике, лечению и профилактике тяжелой внебольничной пневмонии у взрослых. РРО, МАКМАХ. Пульмонология 2014; 4: 13-48.
  4. Feldman C., Anderson R. Antibiotic resistance of pathogens causing community-acquired pneumonia. Semin Respir. Crit. Care Med. 2012, 33: 232-243.
  5. Mayanskiy N., Alyabieva N., Ponomarenko O., Lazareva A., Katosova L., Ivanenko A., Kulichenko T., Namazova-Baranova L., Baranov A. Serotypes and antibiotic resistance of non-invasive Streptococcus pneumoniae circulating in pediatric hospitals in Moscow, Russia. Int. J. Infect. Dis. 2014; 20: 58-62.
  6. Калиногорская О.С., Беланов С.С., Волкова М.О., Гостев B.В., Сидоренко С.В. Антибиотикорезистентность и серотиповый состав Streptococcus pneumoniae, выделенных у детей в Санкт-Петербурге в 2010-2013 гг. Антибиотики и химиотерапия 2015; 60 (1-2): 28-37.
  7. Козлов Р.С., Сухорукова М.В., Сивая О.В., Иванчик Н.В., исследовательская группа ПЕГАС. Чувствительность к антимикробным препаратам клинических штаммов Streptococcus pneumoniae, выделенных в различных регионах РФ в 2010-2013 гг. Клин. микробиол. антимикроб. химиотер. 2015; 17(приложение 2): 31.
  8. Ludwig E., Bonanni P., Rohde G., Sayiner A., Torres A. The remaining challenges of pneumococcal disease in adults. Eur. Respir. Rev. 2012, 21: 57-65.
  9. Козлов Р.С., Чагарян А.Н., Козлова Л.В., Муравьев А.А. Серологическая характеристика и чувствительность к антибиотикам пневмококков, выделенных у детей в возрасте до 5 лет в отдельных регионах Российской Федерации. Клин. микробиол. антимикроб. химиотер. 2011; 13(2): 177-187.
  10. Musher D.M. Pneumococcal vaccination in adults. UpToDate; December 2013.
  11. Sanford M. Pneumococcal polysaccharide conjugate vaccine (13-valent, adsorbed): in older adults. Drugs 2012; 72: 1243- 1255.
  12. Scott L.J., Sanford M. Pneumococcal polysaccharide conjugate vaccine (13-valent, adsorbed): a guide to its use in older adults. Drugs Aging 2012; 29: 847-855.
  13. Иммунизация полисахаридной поливалентной вакциной для профилактики пневмококковой инфекции. Методические рекомендации. (утв. Роспотребнадзором 08.02.2008 № 01/816-8-34). http://www.privivka.ru/ru/ expert/russian/?id=166.
  14. Advisory Committee on Immunization Practices (ACIP). Prevention of pneumococcal diseases: recommendations of the advisory committee on immunization practices. MMWR 1997; 46: 1-24.
  15. Fedson D.S., Nicolas-Spony L., Klemets P., van der Linden M., Marques A., Salleras L., Samson S.I. Pneumococcal polysaccharide vaccination for adults: new perspectives for Europe. Expert Rev. Vaccines 2011; 10: 1143-1167.
  16. Koskela M., Leinonen M., Häivä V.M., Timonen M., Mäkelä P.H. First and second dose antibody responses to pneumococcal polysaccharide vaccine in infants. Pediatr. Infect. Dis. J. 1986; 5: 45-50.
  17. Eskola J., Anttila M. Pneumococcal conjugate vaccines. Pediatr. Infect. Dis. J. 1999; 18: 543-551.
  18. Centers for Disease Control and Prevention (CDC). Updated recommendations for prevention of invasive pneumococcal disease among adults using the 23-valent pneumococcal polysaccharide vaccine (PPSV23). MMWR 2010; 59: 1102- 1106.
  19. Jackson L.A., Janoff E.N. Pneumococcal vaccination of elderly adults: new paradigms for protection. Clin. Infect. Dis. 2008; 47: 1328-1338.
  20. Pedersen R.H., Lohse N., 0stergaard L., S0gaard O.S. The effectiveness of pneumococcal polysaccharide vaccination in HIV-infected adults: a systematic review. HIV Med. 2011; 12: 323-233.
  21. Blasi F., Mantero M., Santus P., Tarsia P. Understanding the burden of pneumococcal disease in adults. Clin. Microbiol. Infect. 2012; 18: 7-14.
  22. Icardi G., Sticchi L., Bagnasco A., Iudici R., Durando P. Pneumococcal vaccination in adults: rationale, state of the art and perspectives. J. Prev. Med. Hyg. 2012; 53: 78-84.
  23. Musher D.M. How effective is vaccination in preventing pneumococcal disease? Infect. Dis. Clin. North. Am. 2013; 27: 229-41.
  24. Huss A., Scott P., Stuck A.E., Trotter C., Egger M. Efficacy of pneumococcal vaccination in adults: a meta-analysis. CMAJ 2009; 180: 48-58.
  25. Moberley S., Holden J., Tatham D.P., Andrews R.M. Vaccines for preventing pneumococcal infection in adults. Cochrane Database Syst. Rev. 2013; 1: CD000422.
  26. Ochoa-Gondar O., Vila-Corcoles A., Rodriguez-Blanco T., Gomez-Bertomeu F., Figuerola-Massana E., Raga-Luria X., Hospital-Guardiola I. Effectiveness of the 23-valent pneumococcal polysaccharide vaccine against community-acquired pneumonia in the general population ages ≥ 60 years: 3 years of follow-up in the CAPAMIS study. Clin. Infect. Dis. 2014; 58: 909-917.
  27. Wiemken T.L., Carrico R.M., Klein S.L., Jonsson C.B., Peyrani P., Kelley R.R., Aliberti S., Blasi F., Fernandez-Gonzalez R., Lopardo G., Ramirez J.A., CAPO Investigators. The effectiveness of the polysaccharide pneumococcal vaccine for the prevention of hospitalizations due to Streptococcus pneumoniae community-acquired pneumonia in the elderly differs between the sexes: results from the Community Acquired Pneumonia Organization (CAPO) international cohort study. Vaccine 2014; 32: 2198-2203
  28. Leventer-Roberts M., Feldman B.S., Brufman I., Cohen-Stavi C.J., Hoshen M., Balicer R.D. Effectiveness of 23-valent pneumococcal polysaccharide vaccine against invasive disease and hospital-treated pneumonia among people aged > 65 years: a retrospective case-control study. Clin. Infect. Dis. 2015; 60(10): 1472-1480.
  29. Pneumococcal vaccines. WHO position paper - 2012. Weekly Epidemiological Record 2012; 87(14): 129-114.
  30. Torling J., Hedlund J., Konradsen H.B., Ortqvist A. Revaccination with the 23-valent pneumococcal polysaccharide vaccine in middle-aged and elderly persons previously treated for pneumonia. Vaccine 2003; 22: 96-103.
  31. Brynjolfsson S.F., Henneken M., Bjarnarson S.P., Mori E., Del Giudice G., Jonsdottir I. Hyporesponsiveness following booster immunization with bacterial polysaccharides is caused by apoptosis of memory B cells. J. Infect. Dis. 2012; 205: 422-430.
  32. Schenkein J.G., Park S., Nahm M.H. Pneumococcal vaccination in older adults induces antibodies with low opsonic capacity and reduced antibody potency. Vaccine 2008; 26: 5521-5526.
  33. Moderate Pneumonia Protection With PCV-13 in the Elderly. Presented at 16th International Congress on Infectious Diseases (ICID). Abstract 09.004. Presented April 3, 2014.
  34. Centers for Disease Control and Prevention (CDC). Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine for adults with immunocompromising conditions: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 2012; 61: 816-819.
  35. Paradiso P.R. Pneumococcal conjugate vaccine for adults: a new paradigm. Clin. Infect. Dis. 2012; 55: 259-264.
  36. Pilishvili T., Lexau C., Farley M.M., Hadler J., Harrison L.H., Bennett N.M., Reingold A., Thomas A., Schaffner W., Craig A.S., Smith P.J., Beall B.W., Whitney C.G., Moore M.R., Active Bacterial Core Surveillance/Emerging Infections Program Network. Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine. J. Infect. Dis. 2010; 201: 32-41.
  37. Griffin M.R., Zhu Y., Moore M.R., Whitney C.G., Grijalva C.G. U.S. hospitalizations for pneumonia after a decade of pneumococcal vaccination. N. Engl. J. Med. 2013; 369: 155-163.
  38. Siber G.R. Pneumococcal disease; prospects for a new generation of vaccines. Science 1994; 265: 1385-1387.
  39. Whitney C.G., Farley M.M., Hadler J., Farley M.M., Reingold A., Harrison L., Lefkowitz L., Danila R., Stefonek K., Barrett N., Morse D., Pinner R., Active Bacterial Core Surveillance Team of the Emerging Infections Program Network. N. Engl. J. Med. 2003; 348: 1737-1746.
  40. Invasive Pneumococcal Disease in Children 5 Years After Conjugate Vaccine Introduction - Eight States, 1998-2005. MMWR 2008; 57: 144-148.
  41. Kyaw M.H., Lynfield R., Schaffner W., Craig A.S., Hadler J., Reingold A., Thomas A.R., Harrison L.H., Bennett N.M., Farley M.M., Facklam R.R., Jorgensen J.H., Besser J., Zell E.R., Schuchat A., Whitney C.G., Active Bacterial Core Surveillance of the Emerging Infections Program Network. Effect of introduction of the pneumococcal conjugate vaccine on drug-resistant Streptococcus pneumonia. N. Engl. J. Med. 2006; 354(14): 1455-1463.
  42. Grivea I.N., Panagiotou M., Tsantouli A.G., Syrogiannopoulos G.A. Impact of heptavalent pneumococcal conjugate vaccine on nasopharyngeal carriage of penicillin-resistant Streptococcus pneumoniae among day-care center attendees in central Greece. Pediatr. Infect. Dis J. 2008; 27(6): 519-525.
  43. Hausdorff W.P., Feikin D.R., Klugman K.P. Epidemiological differences among pneumococcal serotypes. Lancet 2005; 5: 83-93.
  44. Ongkasuwan J., Valdez T.A., Hulten K.G., Mason E.O.Jr., Kaplan S.L. Pneumococcal mastoiditis in children and the emergence of multidrug-resistant serotype 19A isolates. Pediatrics 2008; 122(1): 34-39.
  45. Tatochenko V., Sidorenko S., Namazova-Baranova L., Mayanskiy N., Kulichenko T., Baranov A., Lobzin Y., Kharit S., Kozlov R., Andreeva I., Muravjev A., Chagaryan A., Koroleva I., Beloshitskiy G., Mironov K., Degtyareva E., Reinert R. Streptococcus pneumoniae serotype distribution in children in the Russian Federation before the introduction of pneumococcal conjugate vaccines into the National Immunization Program. Expert Rev. Vaccines. 2014; 13(2): 257-264.
  46. Pneumococcal Vaccine Works on Virulent Strains. IDWeek 2013, Abstract 443. Presented October 3, 2013.
  47. Pfizer Receives European Approval to Extend Use of Prevenar 13 to Adults 50 Years and Older for the Prevention of Invasive Pneumococcal Disease (Press Release). http://press.pfizer.com/press-release/pfizer-receives-european-approval-extend-use-prevenar-13-adults-50-years-andolder-pre (July 27, 2015).
  48. Centers for Disease Control and Prevention (CDC). Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine for adults with immunocompromising conditions: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 2012; 61: 816-819.
  49. Jackson L.A., Gurtman A., van Cleeff M., Jansen K.U., Jayawardene D., Devlin C., Scott D.A., Emini E.A., Gruber W.C., Schmoele-Thoma B. Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine compared to a 23-valent pneumococcal polysaccharide vaccine in pneumococcal vaccine-naive adults. Vaccine 2013; 31: 3577-3584.
  50. Jackson L.A., Gurtman A., van Cleeff M., Frenck R.W., Treanor J., Jansen K.U., Scott D.A., Emini E.A., Gruber W.C., Schmoele-Thoma B. Influence of initial vaccination with 13-valent pneumococcal conjugate vaccine or 23-valent pneumococcal polysaccharide vaccine on anti-pneumococcal responses following subsequent pneumococcal vaccination in adults 50 years and older. Vaccine 2013; 31: 3594-3602.
  51. Greenberg R.N., Gurtman A., Frenck R.W., Strout C., Jansen K.U., Trammel J., Scott D.A., Emini E.A., Gruber W.C., Schmoele-Thoma B. Sequential administration of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine in pneumococcal vaccine-naive adults 60-64 years of age. Vaccine 2014; 32: 2364-2374.
  52. Jackson L.A., Gurtman A., Rice K., Pauksens K., Greenberg R.N., Jones T.R., Scott D.A., Emini E.A., Gruber W.C., Schmoele-Thoma B. Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine in adults 70 years of age and older previously vaccinated with 23-valent pneumococcal polysaccharide vaccine. Vaccine 2013; 31: 3585-3593.
  53. Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine among children aged 6-18 years with immunocompromising conditions: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 2013; 62(25): 521-524.
  54. Tomczyk S., Bennett N.M., Stoecker C., Gierke R., Moore M.R., Whitney C.G., Hadler S., Pilishvili T.; Centers for Disease Control and Prevention (CDC). Use of 13-Valent Pneumococcal Conjugate Vaccine and 23-Valent Pneumococcal Polysaccharide Vaccine Among Adults Aged > 65 Years: Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 2014; 63(37): 822-825.
  55. Bonten M.J., Huijts S.M., Bolkenbaas M., Webber C., Patterson S., Gault S., van Werkhoven C.H., van Deursen A.M., Sanders E.A., Verheij T.J., Patton M., McDonough A., Moradoghli-Haftvani A., Smith H., Mellelieu T., Pride M.W., Crowther G., Schmoele-Thoma B., Scott D.A., Jansen K.U., Lobatto R., Oosterman B., Visser N., Caspers E., Smorenburg A., Emini E.A., Gruber W.C., Grobbee D.E. Polysaccharide Conjugate Vaccine Against Pneumococcal Pneumonia in Adults. N. Engl. J. Med. 2015; 372: 1114-1125.
  56. Smith K.J., Wateska A.R., Nowalk M.P., Raymund M., Nuorti J.P., Zimmerman R.K. Cost-effectiveness of adult vaccination strategies using pneumococcal conjugate vaccine compared with pneumococcal polysaccharide vaccine. JAMA 2012; 307: 804-812.
  57. Smith K.J., Nowalk M.P., Raymund.M, Zimmerman R.K. Cost-effectiveness of pneumococcal conjugate vaccination in immunocompromised adults. Vaccine 2013; 31: 3950-3956.
  58. Smith K.J., Wateska A.R., Nowalk M.P., Raymund M., Lee B.Y., Zimmerman R.K. Modeling of cost effectiveness of pneumococcal conjugate vaccination strategies in U.S. older adults. Am. J. Prev. Med. 2013; 44: 373-381.
  59. Приказ Министерства здравоохранения РФ от 21 марта 2014 г. №125н «Об утверждении национального календаря профилактических прививок РФ и календаря профилактических прививок по эпидемическим показаниям». http://base.garant. ru/70647158/
  60. Hicks L.A., Harrison L.H., Flannery B., Hadler J.L., Schaffner W., Craig A.S., Jackson D., Thomas A., Beall B., Lynfield R., Reingold A., Farley M.M., Whitney C.G. Incidence of pneumococcal disease due to non-pneumococcal conjugate vaccine (ПКВ7) serotypes in the United States during the era of widespread ПКВ7 vaccination, 1998-2004. J. Infect. Dis. 2007; 196: 1346 - 1354.
  61. Miller E., Andrews N.J., Waight P.A., Slack M.P., George R.C. Herd immunity and serotype replacement 4 years after seven-valent pneumococcal conjugate vaccination in England and Wales: an observational cohort study. Lancet Infect. Dis. 2011; 10: 760-768.
  62. Weinberger D.M., Malley R., Lipsitch M. Serotype replacement in disease after pneumococcal vaccination. Lancet 2011; 378: 1962-1973.
  63. Feikin D.R., Kagucia E.W., Loo J.D., Link-Gelles R., Puhan M.A., Cherian T., Levine O.S., Whitney C.G., O’Brien K.L., Moore M.R., Serotype Replacement Study Group. Serotype-specific changes in invasive pneumococcal disease after pneumococcal conjugate vaccine introduction: a pooled analysis of multiple surveillance sites. PLoS Med. 2013; 10: e1001517.

Дополнительные файлы

Доп. файлы
Действие
1. JATS XML
Скачать

Данный сайт использует cookie-файлы

Продолжая использовать наш сайт, вы даете согласие на обработку файлов cookie, которые обеспечивают правильную работу сайта.

О куки-файлах